Dr. Lal Pathlabs Ltd (LALPATHLAB) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539524 | NSE: LALPATHLAB | Hospital & Healthcare Services | Small Cap

Dr. Lal Pathlabs Share Price

2,999.90 -54.55 -1.79%
as on 05-Dec'25 12:12

Dr. Lal Pathlabs Ltd (LALPATHLAB) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539524 | NSE: LALPATHLAB | Hospital & Healthcare Services | Small Cap

DeciZen - make an informed investing decision on Dr. Lal Pathlabs

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Dr. Lal Pathlabs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
47.57
Market Cap:
25,588.8 Cr.
52-wk low:
2,295.1
52-wk high:
3,542.6

Is Dr. Lal Pathlabs Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Dr. Lal Pathlabs: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dr. Lal Pathlabs Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 48.2%43.5%37.7%34.3%32.6%34.8%32.3%22.7%26.8%32%-
Value Creation
Index
2.62.21.81.51.41.61.90.71.01.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7658821,0241,1651,2741,4911,8791,7692,1252,3522,446
Sales YoY Gr.-15.2%16.1%13.8%9.3%17%26.1%-5.8%20.1%10.7%-
Adj EPS 15.218.420.123.226.133.641.834.941.659.764.2
YoY Gr.-21%9.4%15.1%12.7%28.8%24.2%-16.4%18.9%43.6%-
BVPS (₹) 57.969.691108.3118141.3169.7195.7209.6248.5279.4
Adj Net
Profit
126153168193218280348291347499538
Cash Flow from Ops. 142167189209272373426428505540-
Debt/CF from Ops. 0000000.80.60.20-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 13.3%13.1%7.8%10.7%
Adj EPS 16.4%18%12.6%43.6%
BVPS17.6%16.1%13.6%18.6%
Share Price - 6.1% 6.4% 0.5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
31.528.724.622.622.325.125.918.419.925.424.3
Op. Profit
Mgn %
26.426.12524.325.727.327.52627.328.428.7
Net Profit
Mgn %
16.417.316.416.617.118.818.516.516.321.222
Debt to
Equity
0000000.20.20.100
Working Cap
Days
6666666252453638354196
Cash Conv.
Cycle
-15-10-12-13-15-21-19-21-24-2467

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Dr. Lal Pathlabs Ltd.

Standalone Consolidated
TTM EPS (₹) 64.2 63.8
TTM Sales (₹ Cr.) 2,446 2,600
BVPS (₹.) 279.4 285
Reserves (₹ Cr.) 2,257 2,304
P/BV 10.93 10.72
PE 47.57 47.87
From the Market
52 Week Low / High (₹) 2295.10 / 3542.60
All Time Low / High (₹) 696.50 / 4243.00
Market Cap (₹ Cr.) 25,589
Equity (₹ Cr.) 83.8
Face Value (₹) 10
Industry PE 90.5

Management X-Ray of Dr. Lal Pathlabs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Dr. Lal Pathlabs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Dr. Lal Pathlabs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales7658821,0241,1651,2741,4911,8791,7692,1252,352
Operating Expenses 5646527688829461,0831,3661,3081,5441,686
Manufacturing Costs30147178205233267363380439485
Material Costs168191219255287374448390428455
Employee Cost 133147175202232257321316403458
Other Costs 232166195220193185234224275289
Operating Profit 202230256283328407512461581665
Operating Profit Margin (%) 26.4%26.1%25.0%24.3%25.7%27.3%27.3%26.0%27.3%28.3%
Other Income 222832465851534766112
Interest 0111151529342921
Depreciation 3226313668707682136134
Exceptional Items 0000000000
Profit Before Tax 192231256292303374461391483621
Tax 66798797809411698136124
Profit After Tax 126152168195223280345292347497
PAT Margin (%) 16.4%17.3%16.4%16.8%17.5%18.8%18.4%16.5%16.3%21.1%
Adjusted EPS (₹)15.218.420.223.526.833.641.435.141.559.5
Dividend Payout Ratio (%)16%16%22%26%45%60%29%34%58%40%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 4795787599039831,1771,4151,6321,7502,078
Share Capital 83838383838383838384
Reserves 3964956758199001,0941,3311,5481,6661,994
Minority Interest0000000000
Debt00000026215300
Long Term Debt0000001678300
Short Term Debt000000957000
Trade Payables41516277113136123140180193
Others Liabilities 61355865200233380362375266
Total Liabilities 5806638791,0451,2961,5462,1812,2882,3052,536

Fixed Assets

Gross Block3071472262624495206677361,6671,740
Accumulated Depreciation177265489152220296374596722
Net Fixed Assets 1301211731732973003713611,0711,018
CWIP 4179311914563
Investments 741341742142531711,0621,213213416
Inventories14172728553940233332
Trade Receivables354040535064676387105
Cash Equivalents 207235307478549889543534752768
Others Assets 117981509781758487144194
Total Assets 5806638791,0451,2961,5462,1812,2882,3052,536

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 142167189209272373426428505540
PBT 192152256292303374461391483621
Adjustment 11901794659889612075
Changes in Working Capital 6-88101337-64030-1
Tax Paid -67-68-92-102-89-97-118-99-128-155
Cash Flow From Investing Activity -148-134-166-93-19-195-449-2881-293
Capex -42-49-66-39-48-35-68-38-52-52
Net Investments -111-92-118-7947-174512-2688-325
Others 571825-1814-892174684
Cash Flow From Financing Activity 1-3213-54-187-136141-270-411-325
Net Proceeds from Shares 1744400001313
Net Proceeds from Borrowing 0000000-83-830
Interest Paid -1-0-0-0-15-15-29-34-29-21
Dividend Paid -15-37-31-54-153-99-116-99-199-200
Others -01-0-0-19-22286-54-103-116
Net Cash Flow -5136616542118-13195-78

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)32.6228.8725.1823.5323.6625.9326.6419.1920.5125.99
ROCE (%)48.1543.5337.6534.3432.634.8232.2722.7126.8331.99
Asset Turnover Ratio1.521.421.331.211.091.051.010.790.930.97
PAT to CFO Conversion(x)1.131.11.131.071.221.331.231.471.461.09
Working Capital Days
Receivable Days15161415151413131315
Inventory Days768912128755
Payable Days808794100121121106123137150

Dr. Lal Pathlabs Ltd Stock News

Dr. Lal Pathlabs Ltd FAQs

The current trading price of Dr. Lal Pathlabs on 05-Dec-2025 12:12 is ₹2,999.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Dr. Lal Pathlabs stood at ₹25,588.8.
The latest P/E ratio of Dr. Lal Pathlabs as of 04-Dec-2025 is 47.57.
The latest P/B ratio of Dr. Lal Pathlabs as of 04-Dec-2025 is 10.93.
The 52-week high of Dr. Lal Pathlabs is ₹3,542.6 and the 52-week low is ₹2,295.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Lal Pathlabs is ₹2,446 ( Cr.) .

About Dr. Lal Pathlabs Ltd

The company was incorporated as ‘Dr. Lal PathLabs Private Limited’, a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana (RoC) on February 14, 1995 at Delhi. Subsequently, the name of the company was changed to ‘Dr. Lal PathLabs Limited’ upon conversion of the company into a public limited company pursuant to a special resolution of the shareholders of the company dated August 7, 2015 and a fresh certificate of incorporation was issued by the RoC on August 19, 2015. There has been no change in the registered office of the company since incorporation of the company.

The company focuses on providing patients quality diagnostic and related healthcare tests and services. The company’s focus on the patient as a customer is a critical differentiator in the diagnostic and healthcare industries and, together with what its brand’s recognition for quality diagnostic services, results in individuals and healthcare providers choosing it as their diagnostic healthcare service provider. This is because (i) in India, patients generally choose their diagnostic healthcare service provider and (ii) patients and healthcare providers seek quality healthcare service providers due to what range in quality and reliability of diagnostic healthcare services in India.

With over 3,368 diagnostic and related healthcare tests and services offered, the company is capable of performing substantially all of the diagnostic healthcare tests and services currently prescribed by physicians in India. Its diagnostic and related healthcare tests and services include (i) routine clinical laboratory tests - such as blood chemistry analyses and blood cell counts; (ii) specialized testing services - such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and (iii) preventive testing services - such as screenings for hypertension, heart disease and diabetes. It performs these tests and services in its clinical laboratories using sophisticated and computerized instruments.

The company has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi. The company’s “hub and spoke” model, whereby specimens are collected across multiple locations within a region for delivery to a predesignated clinical laboratory for centralized diagnostic testing, provides greater economies of scale and offers a scalable platform for the continued growth of its business. Its network is present across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. The company’s centralized information technology platform fully integrates its large network through a common logistics and payments system and tracks its operations and internal performance metrics, thereby enabling it to improve the efficiencies of its business.

Business area of the company

The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

Awards and accreditations

  • 2001: Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services, including in clinical trials.
  • 2002: Fully accredited by the College of American Pathologists’ Laboratory Accreditation Program.
  • 2008: Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category.
  • 2010: Franchisor of the Year in healthcare, at the Franchise Plus Awards.
  • 2010: Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards.
  • 2012: Diagnostic Service Provider Company of the Year, by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards.
  • 2012: Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research, develop new diagnostic methods and services and improve quality and access of patients to healthcare.
  • 2013: Best Diagnostic Company in India at the VC Circle Healthcare Summit.
  • 2014: Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions.
  • 2014: Received an NABL certificate of accreditation under standard ISO 15189:2012 for “Medical Laboratories - Requirements for Quality and Competence” for medical testing, for National Reference Laboratory.
  • 2015: Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the ‘Cloud’ category.
  • 2015: Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon, Haryana, India.

Major events and milestones

  • 2005, 2007: Investment by WestBridge I Investments Holdings.
  • 2008: Acquisition of Paliwal Medicare and Paliwal Diagnostics.
  • 2010: Establishment of its National Reference Laboratory.
  • 2010, 2013: Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings.
  • 2013: Investment pursuant to purchase of shares by WestBridge Crossover Fund, LLC from WestBridge I Investment Holdings.
  • 2013: Investment by SIH.
  • 2014: Acquisition of APL Clinical Institute of Clinical Laboratory & Research.
  • 2015: Amalgamation of Sanya Chemicals Private, Amolak Diagnostics, Medex Healthcare, Medicave Diagnostic Centre, Medicave Medical Systems and the company.
  • 2016: the Parent Company has set up new/acquired laboratories at various locations in India and some new patient service centers at various locations.
  • 2017: The Company had acquired 10% addiOonal equity stake in its exisOng two subsidiaries - Paliwal DiagnosOc Private Limited (PDPL) and Paliwal Medicave Private Limited (PMPL).
  • 2017: the Company has acquired 100% equity stake in “Delta Ria and Pathology Private Limited”, engaged in the business of providing pathological diagnosOcs services in Bhopal.
  • 2019: Company’s Wholly Owned Subsidiary viz M/s PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company.
  • 2019: The company acquired 70% equity stake in “APRL PathLabs Private Limited”, engaged in the business of providing pathological diagnostics services, on a going concern basis.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×